Figure 10. Seizure freedom rates at 3 months, 6 months, 12 months and at last visit for patients who received eslicarbazepine acetate as initial monotherapy and eslicarbazepine acetate as initial adjunctive therapy. Seizure freedom was defined as no seizures since at least the prior visit (either 3 or 6 months). Statistical comparisons were conducted using the Chi-squared test. Reproduced with permission from Eisai